日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma

FAK抑制剂联合RAF-MEK钳制抑制剂avutometinib可克服BRAF V600E黑色素瘤对靶向治疗和免疫疗法的耐药性。

Simone Lubrano,Rodolfo Daniel Cervantes-Villagrana,Farhoud Faraji,Sydney Ramirez,Kuniaki Sato,Sendi R Adame-Garcia,Adam Officer,Nadia Arang,Damiano C Rigiracciolo,Paola Y Anguiano Quiroz,Claudia Martini,YiYu Wang,Fleur M Ferguson,Antonietta Bacchiocchi,Ruth Halaban,Silvia Coma,Sheri L Holmen,Jonathan A Pachter,Andrew E Aplin,J Silvio Gutkind

High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

高通量化学遗传药物筛选揭示 PKC-RhoA/PKN 是 GNAQ 驱动的葡萄膜黑色素瘤中可靶向的信号通路脆弱性

Nadia Arang ,Simone Lubrano ,Michele Ceribelli ,Damiano C Rigiracciolo ,Robert Saddawi-Konefka ,Farhoud Faraji ,Sydney I Ramirez ,Daehwan Kim ,Frances A Tosto ,Erica Stevenson ,Yuan Zhou ,Zhiyong Wang ,Julius Bogomolovas ,Alfredo A Molinolo ,Danielle L Swaney ,Nevan J Krogan ,Jing Yang ,Silvia Coma ,Jonathan A Pachter ,Andrew E Aplin ,Dario R Alessi ,Craig J Thomas ,J Silvio Gutkind

Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry

全基因组 CRISPR 筛选确定 PI3K/AKT 是致癌 GNAQ-粘着斑激酶信号通路的下游成分

Nadia Arang, Simone Lubrano, Damiano Cosimo Rigiracciolo, Daniela Nachmanson, Scott M Lippman, Prashant Mali, Olivier Harismendy, J Silvio Gutkind

Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC)

粘着斑激酶 (FAK)-Hippo/YAP 转导信号介导 S100A8/A9-RAGE 系统在三阴性乳腺癌 (TNBC) 中发挥的刺激作用

Damiano Cosimo Rigiracciolo, Nijiro Nohata, Rosamaria Lappano, Francesca Cirillo, Marianna Talia, Sendi Rafael Adame-Garcia, Nadia Arang, Simone Lubrano, Ernestina Marianna De Francesco, Antonino Belfiore, J Silvio Gutkind, Marcello Maggiolini

Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma

合成致死筛选揭示了 FAK 和 MEK 的共靶向性,可作为 GNAQ 驱动的葡萄膜黑色素瘤的多模式精准疗法

Justine S Paradis #, Monica Acosta #, Robert Saddawi-Konefka, Ayush Kishore, Frederico Gomes, Nadia Arang, Manoela Tiago, Silvia Coma, Simone Lubrano, Xingyu Wu, Kyle Ford, Chi-Ping Day, Glenn Merlino, Prashant Mali, Jonathan A Pachter, Takami Sato, Andrew E Aplin, J Silvio Gutkind

A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK

合成致死基因相互作用网络平台揭示 GNAQ 葡萄膜黑色素瘤致癌基因通过 FAK 控制 Hippo 通路

Xiaodong Feng, Nadia Arang, Damiano Cosimo Rigiracciolo, Joo Sang Lee, Huwate Yeerna, Zhiyong Wang, Simone Lubrano, Ayush Kishore, Jonathan A Pachter, Gabriele M König, Marcello Maggiolini, Evi Kostenis, David D Schlaepfer, Pablo Tamayo, Qianming Chen, Eytan Ruppin, J Silvio Gutkind

The landscape of BRAF transcript and protein variants in human cancer

人类癌症中 BRAF 转录本和蛋白质变体概况

Andrea Marranci, Zhijie Jiang, Marianna Vitiello, Elena Guzzolino, Laura Comelli, Samanta Sarti, Simone Lubrano, Cinzia Franchin, Ileabett Echevarría-Vargas, Andrea Tuccoli, Alberto Mercatanti, Monica Evangelista, Paolo Sportoletti, Giorgio Cozza, Ettore Luzi, Enrico Capobianco, Jessie Villanueva, G